Takeaways From Our Noema Pharma Webinar

Research evidence excerpt

Takeaways From Our Noema Pharma Webinar

Biotechnology

EQUITY RESEARCH Industry Report

May 14, 2026

Research Analysts:

As part of our ongoing Private Company Series, we hosted a webinar with Olivia Brayer Saunders

212-428-5907 the Noema Pharma team (CEO Ilise Lombardo) to review the company’s

Olivia.Brayer@cantor.com broader CNS strategy, clinical progress across its pipeline, and some of their

Josh Schimmer recent phase 2 data. We covered a lot: lots to discuss on the trigeminal

310-282-6513 neuralgia (TN) opportunity, the regulatory framework in neuropathic pain, Josh.Schimmer@cantor.com

cendifensine in vasomotor symptoms (VMS), and much more.

Reach out for the replay!

Noema Pharma Overview

Noema (private) is a clinical-stage CNS company developing therapies for

underserved neurological and neuropsychiatric disorders. The company’s

portfolio includes three assets that originated from Roche, with a focus

on indications characterized by significant unmet need, limited innovation,

and challenging symptom burden.

A recurring theme throughout the discussion was that many

CNS indications remain significantly underserved despite mechanistic

advances in neuroscience.

●The company is prioritizing indications where currently available

therapies are limited by tolerability, efficacy durability, or treatment

burden

●Noema emphasized the importance of selecting clinically meaningful

endpoints and minimizing trial “noise” in highly variable CNS disorders

The pipeline already has multiple mid-stage programs:

●Basimglurant (mGluR5 MOA) in trigeminal neuralgia, which will move

into phase 3 later this year

●Cendifensine (monoamine modulator) for VMS

●Gemlapodect (PDE10A inhibitor) for Tourette Syndrome, although we

didn't spend time on this one

Basimglurant in Trigeminal Neuralgia (TN)